30 closest matches · ranked by relevance
Muckle Wells Syndrome
Primary: Percent of Participants With Disease Flare in Part II (After 24 Weeks of the Double-blind Part) — 0; 81.3 percent of participants
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: Percentage of Participants Aged 4 Years or Younger With at Least One Complete Response at Week 56 — 94.1 Percentage of participants
Cryopyrin-Associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle Wells Syndrome
Primary: The Number of Participants With Adverse Events (AEs), Death, Serious Adverse Events (SAEs), Discontinuation of Study Drug Due to an AE, Infections and Infestations and…
Familial Cold Autoinflammatory Syndrome (FCAS) · Familial Cold Urticaria · Muckle-Wells Syndrome (MWS)
Primary: Change From Baseline to Week-6 (Part A) Endpoint in Mean Key Symptom Score (KSS) — 2.4; 3.1; 2.1; 0.5 Units of a Scale — p=<.0001
Cryopyrin-associated Periodic Syndromes · Familial Cold Autoinflammatory Syndrome · Muckle-Wells Syndrome
Primary: The Percentage of Participants Without Disease Relapse as Determined by the Physician's Global Assessment of Autoinflammatory Disease Activity, Assessment of Skin…
Inflammation · Familial Mediterranean Fever · Still's Disease, Adult-Onset
Primary: Mean Change in Daily Scores — -3.09 units on a scale
Macrophage Activation Syndrome · Secondary Hemophagocytic Lymphohistiocytosis · Still Disease
Primary: Proportion of Subjects With Complete Response (CR) at Week 8 After First Administration of Emapalumab — 11; 4 Participants
Macrophage Activation Syndrome · Lymphohistiocytosis, Hemophagocytic · Arthritis, Juvenile
Primary: Incidence, Severity, Causality, and Outcomes of AEs (Serious and Nonserious) — 13; 6; 2; 10 Participants
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Familial Mediterranean Fever
Primary: To Assess the Efficacy of Rilonacept in Decreasing the Number of Acute FMF Attacks. — 0.77; 2.00 number of attacks per month — p=0.027
Wegener's Granulomatosis
Primary: Remission of Vasculitis — 95 Percentage of participants
Mevalonate Kinase Deficiency
Primary: Number of Flares Per Participant During Historical Period and Treatment Period — 5; 0 Number of flares
Churg-Strauss Syndrome · Eosinophilic Granulomatosis With Polyangiitis
Primary: Number of Participants With Any Adverse Events (AEs), Serious Adverse Events (SAEs) and Adverse Events of Special Interests (AESI) — 69; 26; 42 Participants
NLRC4-MAS · XIAP Deficiency
Primary: Prevention of Flares — 2.71; NA Weeks
Sanfilippo Syndrome
Primary: Number of Participants With Overall Response Using Bayley Scales of Infant Development Assessment Third Edition (BSID-III) — 0; 2; 1 participants — p=0.4615
Systemic Lupus Erythematosus
Primary: Cohort A: Change From Baseline in Cutaneous Lupus Erythematosus Disease Area and Severity Index-A (CLASI-A) Total Score at Week 16 — -5.0; -9.0; -10.2; -9.7 scores on a…
Chronic Spontaneous Urticaria
Primary: Reduction in Urticaria Activity Score (UAS7) — 3; 7 Participants
Cold Contact Urticaria
Primary: Change in Critical Temperature Thresholds (CTT) From Baseline to Day 70 After Treatment With Omalizumab Compared to Placebo — -10.6; -10.4; -0.3 degree celcius — p=0.001
Wegener's Granulomatosis
Primary: Safety of Abatacept - Number of Participants With Adverse Events — 7; 16; 14; 1 participants
Systemic Sclerosis
Primary: Change in Modified Rodnan Skin Score (MRSS) — -10; -3.0 units on a scale
Systemic Lupus Erythematosus (SLE)
Primary: Number of Participants With Treatment-Emergent Adverse Events — 34; 31; 30; 11 participants
Aicardi Goutieres Syndrome
Primary: Mean and Standard Deviation (SD) of the AGS Scale at 52 Weeks — 5.9 score on a scale — p=<0.0005
Mucopolysaccharidosis (MPS)
Primary: Number of Treatment Emergent Serious Adverse Events (SAE) — 5; 3; 2 events
Primary Sjögren Syndrome
Primary: Change in The European League Against Rheumatism (EULAR) Sjogren's Syndrome Patient Reported Index (ESSPRI) Score From Baseline to Week 24 — -0.125 score on a scale
Systemic Lupus Erythematosus
Primary: Number of Participants With Each Category of Adverse Events in Stage I — 5; 4; 5; 5 Participants
Mucopolysaccharidosis Type I · Mucopolysaccharidosis Type II · Mucopolysaccharidosis Type VI
Primary: Children's Health Questionnaire - Parent Form 50 Bodily Pain Standardized Score — 1.4; 1.0 units on a scale
Sjogren's Syndrome
Primary: Blood Cell Gene Expression — -0.0291486; 0.1330903; 0.2509076; 0.06726222 log 2 fold change — p=0.0000496
Systemic Lupus Erythematosus
Primary: Overall Summary of Adverse Events — 6; 5; 6; 1 Participants
Systemic Lupus Erythematosus
Primary: Percentage of Participants Achieving an Systemic Lupus Erythematosus (SLE) Responder Index [SRI (4)] Response With Oral Corticosteroids (OCS) Tapering at Day 169 — 17.6…
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs) — 101; 27 participants